Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
Total Valuation
Edwards Lifesciences has a market cap or net worth of $43.83B. The enterprise value is $42.68B.
Market Cap$43.83B
Enterprise Value$42.68B
Share Statistics
Edwards Lifesciences has 587,100,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding587,100,000
Owned by Insiders0.21%
Owned by Institutions16.92%
Financial Efficiency
Edwards Lifesciences’s return on equity (ROE) is 0.42 and return on invested capital (ROIC) is 11.23%.
Return on Equity (ROE)0.42
Return on Assets (ROA)0.32
Return on Invested Capital (ROIC)11.23%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee344.27K
Profits Per Employee263.91K
Employee Count15,800
Asset Turnover0.42
Inventory Turnover1.06
Valuation Ratios
The current PE Ratio of Edwards Lifesciences is 51.0. Edwards Lifesciences’s PEG ratio is ―.
PE Ratio51.0
PS Ratio―
PB Ratio―
Price to Fair Value4.43
Price to FCF―
Price to Operating Cash Flow57.82
PEG Ratio―
Income Statement
In the last 12 months, Edwards Lifesciences had revenue of 5.44B and earned 4.17B in profits. Earnings per share was 6.98.
Revenue5.44B
Gross Profit4.32B
Operating Income1.38B
Pretax Income1.55B
Net Income4.17B
EBITDA1.72B
Earnings Per Share (EPS)6.98
Cash Flow
In the last 12 months, operating cash flow was 794.90M and capital expenditures -187.00M, giving a free cash flow of 607.90M billion.
Operating Cash Flow794.90M
Free Cash Flow607.90M
Free Cash Flow per Share1.04
Dividends & Yields
Edwards Lifesciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.85
52-Week Price Change13.05%
50-Day Moving Average78.40
200-Day Moving Average74.72
Relative Strength Index (RSI)37.23
Average Volume (3m)4.25M
Important Dates
Edwards Lifesciences upcoming earnings date is Oct 30, 2025, After Close (Confirmed).
Last Earnings DateJul 24, 2025
Next Earnings DateOct 30, 2025
Ex-Dividend Date―
Financial Position
Edwards Lifesciences as a current ratio of 4.18, with Debt / Equity ratio of 6.66%
Current Ratio4.18
Quick Ratio3.45
Debt to Market Cap0.01
Net Debt to EBITDA-1.36
Interest Coverage Ratio72.94
Taxes
In the past 12 months, Edwards Lifesciences has paid 152.10M in taxes.
Income Tax152.10M
Effective Tax Rate0.10
Enterprise Valuation
Edwards Lifesciences EV to EBITDA ratio is 24.32, with an EV/FCF ratio of 144.54.
EV to Sales7.70
EV to EBITDA24.32
EV to Free Cash Flow144.54
EV to Operating Cash Flow77.27
Balance Sheet
Edwards Lifesciences has $4.06B in cash and marketable securities with $702.60M in debt, giving a net cash position of $3.36B billion.
Cash & Marketable Securities$4.06B
Total Debt$702.60M
Net Cash$3.36B
Net Cash Per Share$5.72
Tangible Book Value Per Share$11.89
Margins
Gross margin is 78.84%, with operating margin of 26.55%, and net profit margin of 76.75%.
Gross Margin78.84%
Operating Margin26.55%
Pretax Margin28.46%
Net Profit Margin76.75%
EBITDA Margin31.68%
EBIT Margin28.82%
Analyst Forecast
The average price target for Edwards Lifesciences is $88.39, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$88.39
Price Target Upside17.43% Upside
Analyst ConsensusModerate Buy
Analyst Count26
Revenue Growth Forecast-5.23%
EPS Growth Forecast-39.83%